Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety of Lorlatinib

Status:
Not yet recruiting

Trial end date:
2023-01-03

Target enrollment:

Participant gender:

This is a post approval requirement to study the effect of moderate and severe hepatic impairment on the pharmacokinetics of lorlatinib.

Phase 1

Pfizer